Anika Therapeutics | ANIK - Ordinary Share Capital


Anika Therapeutics reported $13.89M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Abbott USD 1.74B 2.94M Mar/2026
Agenus USD 38.52M 3.2M Mar/2026
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 141.14M 564K Jun/2026
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Halozyme Therapeutics USD 114.04M 4.48M Jun/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Insmed USD 218.28M 1.76M Jun/2026
Integra LifeSciences USD 77.78M 39K Jun/2026
Intrexon USD 0 0 Jun/2024
J&J USD 2.41B 1.35M Mar/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
MacroGenics USD 63.56M 241K Mar/2026
Merit Medical Systems USD 59.71M 55K Jun/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Sanofi EUR 1.21B 8.25M Mar/2026
Smith & Nephew USD 875.95M 11.64K Jun/2026
Stryker USD 383.4M 416K Jun/2026
Veracyte USD 79.79M 1000 Jun/2026
Xencor USD 74.33M 265K Jun/2026
Zimmer Biomet Holdings USD 193.4M 2.1M Jun/2026